Merck & Co. has won U.S. Food and Drug Administration priority review for its application seeking expanded use of its Welireg oral cancer drug in patients with rare tumors that form in and around the ...

The Department of Urology in AIIMS Bhopal successfully treated 13 hormonally active adrenal tumors in the past year using advanced laparoscopic techniques, demonstrating the institution's innovation ...

The FDA accepts and grants priority review to Merck's sNDA for Welireg to treat advanced pheochromocytoma and paraganglioma.

The FDA has accepted a priority review sNDA for Welireg in adults and pediatric patients with advanced or metastatic ...

The FDA has accepted Merck's (MRK) supplemental NDA with priority review for its drug Welireg for the treatment of a rare ...

MicroRNAs (miRNAs) are endogenous small noncoding RNAs that regulate gene expression by either degrading or inhibiting the translation of mRNAs and have significant roles in the development of various ...

Exelixis, Inc. (Nasdaq: EXEL) today announced results from a subgroup analysis of the phase 3 CABINET pivotal study of ...

Priority review for Welireg is based on data from the Phase II LITESPARK-015 trial, which showed promising response rates in patients with advanced, unresectable, or metastatic pheochromocytoma and ...

Bradley resident Rochelle Langlois has battled Stage 4 cancer everywhere from her lungs, spine, adrenal glands, brain, bone ...

The supplemental new drug application is based on data from the Phase 2 LITESPARK-015 trial.

The FDA granted priority review for belzutifan for treating advanced pheochromocytoma and paraganglioma, with a PDUFA date set for May 26, 2025.

Acne, commonly known as pimples, is not linked to cancer. Pimples result from blocked pores, hormonal changes, or stress, and are non-cancerous. Howev ...